Abbott Laboratories (ABT) to Issue Quarterly Dividend of $0.63 on August 17th

Abbott Laboratories (NYSE:ABT) declared a quarterly dividend on Friday, June 12th. Investors of record on Wednesday, July 15th will be given a dividend of 0.63 per share by the healthcare product maker on Monday, August 17th. This represents a c) annualized dividend and a dividend yield of 2.7%. The ex-dividend date of this dividend is Wednesday, July 15th.

Abbott Laboratories has increased its dividend by an average of 0.1%annually over the last three years and has raised its dividend every year for the last 54 years. Abbott Laboratories has a dividend payout ratio of 44.4% meaning its dividend is sufficiently covered by earnings. Equities analysts expect Abbott Laboratories to earn $6.05 per share next year, which means the company should continue to be able to cover its $2.52 annual dividend with an expected future payout ratio of 41.7%.

Abbott Laboratories Stock Performance

Shares of Abbott Laboratories stock traded down $1.84 during midday trading on Monday, hitting $92.09. The company had a trading volume of 1,060,052 shares, compared to its average volume of 12,078,251. The company has a fifty day simple moving average of $89.21 and a 200 day simple moving average of $103.09. The stock has a market cap of $160.41 billion, a price-to-earnings ratio of 25.91, a PEG ratio of 1.62 and a beta of 0.61. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $137.49.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, beating the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The business had revenue of $11.16 billion for the quarter, compared to the consensus estimate of $10.99 billion. During the same period in the prior year, the firm earned $1.09 EPS. The business’s revenue for the quarter was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, analysts predict that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Insider Buying and Selling at Abbott Laboratories

In other Abbott Laboratories news, CFO Philip P. Boudreau acquired 2,200 shares of the stock in a transaction that occurred on Thursday, April 23rd. The stock was bought at an average cost of $91.50 per share, for a total transaction of $201,300.00. Following the completion of the transaction, the chief financial officer owned 2,200 shares of the company’s stock, valued at approximately $201,300. The trade was a ? increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Daniel J. Starks purchased 10,000 shares of the firm’s stock in a transaction dated Monday, April 27th. The stock was acquired at an average cost of $92.65 per share, for a total transaction of $926,500.00. Following the purchase, the director owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. The trade was a 0.15% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 0.46% of the stock is owned by insiders.

Institutional Trading of Abbott Laboratories

Several institutional investors and hedge funds have recently bought and sold shares of ABT. Vanguard Group Inc. raised its position in Abbott Laboratories by 1.4% in the fourth quarter. Vanguard Group Inc. now owns 175,556,716 shares of the healthcare product maker’s stock valued at $21,995,501,000 after purchasing an additional 2,402,408 shares during the period. State Street Corp increased its position in shares of Abbott Laboratories by 2.1% during the fourth quarter. State Street Corp now owns 79,853,782 shares of the healthcare product maker’s stock worth $10,004,880,000 after acquiring an additional 1,627,791 shares during the period. Capital International Investors raised its stake in shares of Abbott Laboratories by 2.6% in the fourth quarter. Capital International Investors now owns 63,229,445 shares of the healthcare product maker’s stock valued at $7,922,519,000 after acquiring an additional 1,614,706 shares in the last quarter. J. Stern & Co. LLP boosted its stake in shares of Abbott Laboratories by 12,439.6% in the 4th quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock valued at $4,926,279,000 after buying an additional 39,005,451 shares during the period. Finally, Capital Research Global Investors increased its position in shares of Abbott Laboratories by 1.0% in the 4th quarter. Capital Research Global Investors now owns 39,169,239 shares of the healthcare product maker’s stock valued at $4,907,523,000 after purchasing an additional 400,400 shares during the last quarter. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.